Temporal dynamics and acquisition of Shiga toxin subtype stx2a within Shiga toxin-producing Escherichia coli in England, 2016 to 2024

An analysis of 12,888 STEC genomes in England from 2016 to 2024 reveals a significant temporal shift toward non-O157 serogroups, particularly O26:H11 and O145:H28, driven by the widespread and increasing prevalence of the high-risk stx2a toxin subtype, underscoring the critical value of genomic surveillance for monitoring emerging public health threats.

The Gist

Imagine a bustling city called England, but instead of people, it's populated by millions of tiny, invisible bacteria. Most of these bacteria are harmless, but a specific group called STEC (Shiga toxin-producing E. coli) are the "villains" of this story. They can make people very sick, causing stomach cramps, bloody diarrhea, and in the worst cases, a dangerous condition called kidney failure (HUS).

This paper is like a 9-year detective report (from 2016 to 2024) written by scientists at the UK Health Security Agency. They used a high-tech "super-microscope" called Whole Genome Sequencing to look at the DNA of over 12,000 of these bacteria to see what was changing over time.

Here is the story they uncovered, broken down into simple parts:

1. The Dangerous Weapon: The "Stx2a" Toxin

Think of these bacteria as soldiers. Some carry a basic weapon, while others carry a super-weapon called Stx2a.

• The Finding: The scientists found that about 1 in 3 of the bacteria they caught had this super-weapon.
• Why it matters: The Stx2a weapon is the one most likely to cause the severe kidney damage (HUS). The paper shows that the number of bacteria carrying this specific super-weapon has been growing steadily, especially after 2020.

2. The Great Shift: The "Big Boss" is Retiring, New Challengers are Rising

For a long time, the most famous villain in this bacterial world was O157 (specifically the O157:H7 type). It was the "Big Boss" that everyone watched out for.

• The Change: The paper shows that the Big Boss (O157) is actually retiring. The number of O157 bacteria is going down.
• The New Challengers: However, the danger isn't disappearing; it's just changing uniforms. Two new groups, O26 and O145, are taking over the spotlight. They are the "new kids on the block" that are rapidly increasing in number.
• The Twist: These new challengers are not just showing up; they are equipped with the Stx2a super-weapon. In fact, they are the main reason why the total number of dangerous bacteria is going up.

3. The "Acquisition" Game: Stealing the Super-Weapon

Bacteria are like pirates; they can swap their DNA (their "blueprints") with each other.

• The Trend: The scientists noticed that more and more different types of bacteria (78 different "families" or serogroups) are stealing the Stx2a super-weapon.
• The Analogy: Imagine a game where only a few teams had a golden trophy (Stx2a). Over the last few years, the trophy has been passed around to more and more teams. Now, almost every team in the league has a chance to win the trophy, making the whole league more dangerous.

4. The Seasonal Rhythm

Just like bears hibernate or birds migrate, these bacteria have a schedule.

• The Pattern: The number of infections spikes in the summer and early autumn. This is likely because people are eating more raw vegetables, having picnics, or swimming in water that might be contaminated by animal droppings during the warmer months.

5. Why This Matters for You

The scientists are sounding an alarm, but it's a helpful one.

• The Old Way: In the past, doctors mostly looked for the "Big Boss" (O157). If they didn't find it, they might have missed the new challengers (O26 and O145).
• The New Way: Thanks to this study, health officials know they need to watch all the different types of bacteria, not just the famous one. They are using DNA sequencing to catch the new challengers early.
• The Goal: By tracking these "super-weapon" carriers, doctors can spot outbreaks faster, warn the public sooner, and potentially save lives by preventing kidney failure.

The Bottom Line

The landscape of bacterial danger in England is changing. The old "Big Boss" is fading, but two new, dangerous groups are rising up, and they are armed with the most toxic weapon available. The good news is that our "detectives" (the scientists) are using advanced technology to keep a close eye on them, ensuring that public health stays one step ahead of the bacteria.

Technical Summary

1. Problem Statement

Shiga toxin-producing Escherichia coli (STEC) are significant public health threats due to their association with severe foodborne gastroenteritis and Hemolytic Uremic Syndrome (HUS). While STEC O157 has historically been the primary concern, non-O157 serogroups are increasingly recognized as causes of severe disease. The severity of STEC infection, particularly the risk of HUS, is strongly linked to the presence of specific Shiga toxin (stx) subtypes. Among these, stx2a is associated with the most severe clinical outcomes.

Despite the known risks, there is a need to understand the temporal dynamics of stx2a acquisition across diverse STEC serogroups in England. Specifically, researchers sought to determine if the increasing prevalence of non-O157 STEC is accompanied by a shift in stx2a carriage, which would represent an emerging public health risk requiring updated surveillance and intervention strategies.

2. Methodology

The study utilized a comprehensive genomic surveillance dataset managed by the UK Health Security Agency (UKHSA).

• Data Source: Whole Genome Sequencing (WGS) data of clinically relevant STEC isolates from human samples in England, collected between 2016 and 2024.
• Data Filtering:
  • Initial extraction from the EnteroBase database filtered for UKHSA submissions, human origin, and English location.
  • Non-E. coli species, non-human samples, and samples lacking raw read data were excluded.
  • Duplicate isolates were removed (except for confirmed mixed infections), and isolates with non-standard serotyping data were excluded.
  • Final Dataset: 12,888 unique STEC isolates (out of 19,429 total E. coli genomes analyzed) with complete serotype and stx gene profiles.
• Analysis:
  • Genotyping: Serotyping (O and H antigens) and stx gene profiling (presence of stx1a, c, d, e and stx2a–g) were determined via established UKHSA pipelines.
  • Statistical & Visual Analysis: Performed using R (packages: dplyr, ggplot2, janitor, patchwork).
  • Metrics: The study quantified the prevalence of stx subtypes, analyzed temporal trends (yearly and monthly), calculated "acquisition dates" (first reported appearance of specific stx profiles per serogroup), and assessed the diversification of stx2a across the STEC population.

3. Key Contributions

• Large-Scale Genomic Surveillance: This is one of the most extensive analyses of STEC in England, covering a 9-year period with over 12,000 sequenced isolates.
• Shift in Epidemiology: The study documents a definitive epidemiological shift where non-O157 serogroups are not only increasing in number but are increasingly harboring the high-risk stx2a subtype.
• Identification of Drivers: The research pinpoints specific serotype-toxin combinations driving the rise in severe cases, moving beyond general serogroup trends to specific pathogenic profiles.
• Acquisition Mapping: By mapping the "first reported date" of stx2a acquisition across different serogroups, the study reveals a continuous diversification of the stx2a reservoir, suggesting ongoing horizontal gene transfer or clonal expansion.

4. Key Results

• Overall Prevalence:

  • Of the 12,888 STEC isolates, 31.9% (n=4,117) harbored stx2a.
  • stx2a was the second most common stx subtype overall (after stx1a), found across 78 unique O serogroups.
  • The most common stx profiles were "stx2a" (18.4%), "stx1a" (14.1%), and "stx1a, stx2c" (13.6%).

• Temporal Trends (2016–2024):

  • There was a marked increase in stx2a-positive isolates, particularly post-2020.
  • Isolates with stx2a jumped from 287 in 2020 to 824 in 2024.
  • Seasonality was observed, with peaks in summer and early autumn.

• Serogroup Dynamics:

  • O157 vs. Non-O157: While O157 remained the single most common serogroup overall, its proportion of stx2a-positive isolates declined steadily. Conversely, non-O157 serogroups showed a steady, significant increase in stx2a carriage.
  • Primary Drivers: The increase in stx2a was driven primarily by two non-O157 serotypes:
    1. STEC O26:H11: Increased from 6 cases in 2016 to 274 in 2024.
    2. STEC O145:H28: Increased from 18 cases in 2016 to 249 in 2024.
  • In 2024, non-O157 groups O26 and O145 were reported more frequently than O157.

• Acquisition and Diversity:

  • stx2a was acquired by new O serogroups continuously throughout the study period.
  • The number of new serogroups acquiring stx2a increased from 5–11 per year (2017–2020) to 10–11 per year (2021–2024).
  • The "stx2a" profile (alone) was the main driver of the increase, though "stx1a, stx2a" was also significant in O26:H11.

5. Significance

• Public Health Risk: The widespread and increasing presence of stx2a in non-O157 serogroups (specifically O26:H11 and O145:H28) indicates a growing risk of severe disease and HUS in the English population.
• Surveillance Value: The study validates the critical importance of routine genomic surveillance. Traditional culture-based methods often underreported non-O157 STEC; WGS allows for precise tracking of high-risk toxin subtypes regardless of serogroup.
• Clinical Implications: Clinicians and public health officials must recognize that severe STEC disease is no longer confined to O157. The specific combination of O26:H11/O145:H28 with stx2a requires close monitoring for early intervention to prevent HUS.
• Future Directions: The findings suggest that stx2a is actively acquiring into diverse genetic backgrounds. Future research should investigate the reservoirs (e.g., specific livestock or environmental sources) and transmission pathways of these emerging high-risk subgroups to inform food safety policies.

In conclusion, the paper demonstrates that the landscape of STEC in England is evolving, with a concerning rise in high-severity stx2a carriage among non-O157 serogroups, necessitating continued and enhanced genomic surveillance.